Vertex wins approval of new cystic fibrosis therapy Alyftrek
Hawkinsight
2024-12-21 09:06:02
1.64W
CTRPhotos/iStock via Getty Images
- The U.S. FDA has approved Vertex Pharmaceuticals' (NASDAQ:VRTX) Alyftrek (vanzacaftor/tezacaftor/deutivacaftor), a once-daily cystic fibrosis treatment.
- The drug is considered a next-in-class triple combination transmembrane conductance regulator (CFTR) modulator. It is approved for those six years and older who have at least one F508del mutation
Disclaimer: The views in this article are from the original Creator and do not represent the views or position of Hawk Insight. The content of the article is for reference, communication and learning only, and does not constitute investment advice. If it involves copyright issues, please contact us for deletion.
